Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
Iscaffpharma have announced that the company’s first US patent, with patent no US 11,840,732 B2 has been issued by the United States Patent and Trademark Office (USPTO) on December 12th, 2023.
The issued patent, Diagnostic methods, protects a method for determining tumour properties based on the unique Iscaffpharma technology whereby patient derived scaffolds (PDS) from human cancer samples are utilized. This method can be used for determining tumour properties and progression of cancer. Furthermore, the issued US patent covers the identification of new cancer therapies using this unique PDS technology, including determining the suitability of such treatments for patients.
Read full pressrelease in English or Swedish here pressrelease-us-patent-240126
